Brexucabtagene autoleucel (new indication: acute lymphoblastic leukemia, patients aged ≥ 26 years)

Subject:

• Active Substance: Brexucabtagene autoleucel
• Name: Tecartus®
• Therapeutic area: Acute lymphoblastic leukemia
• Pharmaceutical company: Gilead Sciences GmbH

Time table:

• Start: 01.10.2022
• Publication of assessment: 02.01.2023
• End of public hearing: 23.01.2023
• Final decision by G-BA: middle of March 2023

Comparative therapy:

• No comparative therapy due to orphan drug designation